David Hoye has been appointed to the Board of Directors of SK3 Group, Inc. (OTCMKTS:SKTO). Hoye is co-founder of Berkeley Bio-Organic Research Laboratories, which was acquired in April of last year. SK3 Group Inc (OTCMKTS:SKTO) On last trading day company shares ended up $0.0125 .
China Hydroelectric Corporation (USD) (NYSE:CHC) shares fell -0.58% in last trading session and ended the day on $3.40. CHC Gross Margin is 52.70% and its return on assets is -0.70%. China Hydroelectric Corporation (USD) (NYSE:CHC) quarterly performance is 1.19%.
Sprint Corporation (NYSE:S) Chief Financial Officer Joe Euteneuer will speak at the 42nd Annual J.P. Morgan Global Technology, Media and Telecom Conference in Boston, Mass. on Monday, May 19 at 8:20 a.m. ET. A live audio webcast of this session may be accessed at www.sprint.com/investors. A replay will be available shortly after the actual presentation time. Sprint Corporation (NYSE:S) shares moved up 0.67% in last trading session and was closed at $9.03, while trading in range of $8.98 – $9.07. Sprint Corporation (NYSE:S) year to date (YTD) performance is 25.77%.
Telecom Italia SpA (ADR) (NYSE:TI) has confirmed that its newly-elected chairman Giuseppe Recchi will no longer be formally classified as an “independent director” in view of the operational nature of some of his powers. The company’s statement on its quarterly results referred to the change in Recchi’s status, confirming that “in light of the mandates received, the chairman has ascertained that he did not fulfil the formal requirements of an ‘independent director’.” Recchi was appointed chairman in April after months of clashes over control of the operator. Telecom Italia SpA (ADR) (NYSE:TI) ended the last trading day at $12.07. Company weekly volatility is calculated as 1.55% and price to cash ratio as 2.18. Telecom Italia SpA (ADR) (NYSE:TI) showed a negative weekly performance of -4.74%.
AstraZeneca plc (ADR) (NYSE:AZN) announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical pany Incyte Corporation. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in bination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360. AstraZeneca plc (ADR) (NYSE:AZN) net profit margin is 8.00% and weekly performance is -0.96%. On last trading day company shares ended up $78.36. Analysts mean target price for the company is $76.67. AstraZeneca plc (ADR) (NYSE:AZN) distance from 50-day simple moving average (SMA50) is 14.56%.